drugset / Trial / NCT00650208

Fasting Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg

NCT00650208

Phase 1 Completed 27 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's lamotrigine 25 mg tablets to GlaxoSmithKline's (GSK) Lamictal® 25 mg tablets following a single, oral 50 mg (2 x 25 mg) dose administration under fasting conditions.

Timeline

Start
2004-07
Primary completion
2004-08
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamotrigine Small molecule 50 mg Oral

Indications

No indication recorded.